Form 4: Artiva Biotherapeutics Insider Receives Stock Grant
Insider Transaction (Form 4)
Ra Capital Management, L.P. and 5 others reported changes in beneficial ownership of Artiva Biotherapeutics, Inc. common stock on September 8, 2026.
Summary
- Grant/award: acquired 13,750 Director Stock Option (Right to Buy) on September 8, 2026; holds 13,750 after (Indirect).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Ra Capital Management, L.P. — Director, 10% owner
RA Capital Healthcare Fund LP — Director, 10% owner
RA Capital Nexus Fund, L.P. — Director
RA Capital Nexus Fund III, L.P. — Director
Peter Kolchinsky — Director, 10% owner
Rajeev M. Shah — Director, 10% owner
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-08 | Grant/award | Director Stock Option (Right to Buy) | 13,750 | — | — | 13,750 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-08 | Grant/award (13,750 shares) |
Keywords
insider transaction, Form 4, ARTV, Artiva Biotherapeutics, Inc., neutral, Ra Capital Management, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Peter Kolchinsky, Rajeev M. Shah
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.